Bevacizumab (Avastin ○ R) Bevacizumab (Avastin ○ R, rhuMAb-VEGF, Genetech Inc.) Receptor humanized antibody against vascular endothelial growth
factor (VEGF), is currently the treatment of colorectal cancer and breast cancer stage Ⅲclinical studies. VEGF regulate angiogenesis, regulation of vascular
permeability and function of anti-apoptotic effects on endothelial cells of neovascularization. Bevacizum ˉ ab monotherapy tumor has made a significant
therapeutic effect, can also enhance anti-tumor efficacy of chemotherapy. In the treatment of metastatic renal cell carcinoma, phase II clinical study in
advance to achieve the expected efficacy endpoint, achieved good efficacy of combination therapy with Xeloda metastatic breast cancer, has entered the
FDA's expedited procedures.
Related Articles: TNF-alpha